SAGE Therapeutics Inc SG7-FF:Frankfurt Stock Exchange

RT Quote | Exchange | EUR
Last | 03/28/24 CET
17.20quote price arrow down-0.10 (-0.58%)
52 week range
15.10 - 55.00
Loading...
  • Open17.50
  • Day High17.50
  • Day Low17.20
  • Prev Close17.80
  • 52 Week High55.00
  • 52 Week High Date06/12/23
  • 52 Week Low15.10
  • 52 Week Low Date08/08/23

Key Stats

  • Market Cap1,155.25M
  • Shares Out60.11M
  • 10 Day Average Volume642.8
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-13.57

KEY STATS

  • Open17.50
  • Day High17.50
  • Day Low17.20
  • Prev Close17.80
  • 52 Week High55.00
  • 52 Week High Date06/12/23
  • 52 Week Low15.10
  • 52 Week Low Date08/08/23
  • Market Cap1,155.25M
  • Shares Out60.11M
  • 10 Day Average Volume642.8
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-13.57

RATIOS/PROFITABILITY

  • EPS (TTM)-8.20
  • P/E (TTM)-2.10
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On SAGE Therapeutics Inc

 

Profile

MORE
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed the two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. The Company is targeting diseases and disorders of the brain across its clinical development and earlier stage pipeline. Its product ZURZUVAE is for the treatment of postpartum depression (PPD) in adults. ZURZUVAE is a neuroactive steroid that is a...
Geno Germano
Independent Chairman of the Board
Barry Greene
President, Chief Executive Officer, Director
Kimi Iguchi
Chief Financial Officer, Treasurer
Address
215 1st St
Cambridge, MA
02142-1213
United States